UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 18, 2010
ONCOGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413 |
|
|
|
|
|
(State or other Jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
Incorporation) |
|
|
|
|
|
|
|
1522 217th Place S.E. |
|
|
Bothell, Washington
|
|
98021 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (425) 686-1500
N/A
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On October 18, 2010, OncoGenex Pharmaceuticals, Inc. issued a press release entitled OncoGenex
Pharmaceuticals, Inc. Announces Proposed Public Offering. A copy of the press release is attached
as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this report, including
the exhibit attached hereto, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall such information be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press Release of OncoGenex Pharmaceuticals, Inc. dated October 18, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
ONCOGENEX PHARMACEUTICALS, INC.
|
|
Date: October 18, 2010 |
/s/ Cameron Lawrence
|
|
|
Cameron Lawrence |
|
|
Principal Financial Officer |
|
|